Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 766-774

  Thakur, Basant Kumar ^a   Dittrich, Tino ^a   Chandra, Prakash ^b   Becker, Annette ^c   Kuehnau, Wolfgang ^a   Klusmann, Jan Henning ^a   Reinhardt, Dirk ^a   Welte, Karl ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

acetylation; FK866; NAMPT; nicotinamide (NA); p53; sirtuins (SIRTs)

Indexed keywords

ADENOSINE TRIPHOSPHATE; DAPORINAD; LYSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SIRTUIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACETYLATION; ACRYLAMIDES; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; GENE KNOCKOUT TECHNIQUES; HUMANS; LEUKEMIA, MYELOID; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84871362358     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27726     Document Type: Article

References (49)

1. Voso MT, D'Alo F, Greco M, et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 2010; 184: 46-9.
2. Fullgrabe J, Kavanagh E, Joseph B,. Histone onco-modifications. Oncogene 2011; 30: 3391-403.
3. Spange S, Wagner T, Heinzel T, et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009; 41: 185-98.
4. Yang XJ, Seto E,. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-18. (Pubitemid 47255917)
5. Michan S, Sinclair D,. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13. (Pubitemid 46788079)
6. Quintas-Cardama A, Santos FP, Garcia-Manero G,. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226-35.
7. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (New York, N.Y.) 2004; 303: 2011-15. (Pubitemid 38393275)
8. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59. (Pubitemid 33035942)
9. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48. (Pubitemid 33035941)
10. Revollo JR, Grimm AA, Imai S,. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-63. (Pubitemid 40017813)
11. Boyapati A, Kanbe E, Zhang DE,. p53 alterations in myeloid leukemia. Acta Haematol 2004; 111: 100-6. (Pubitemid 37499958)
12. Dai C, Gu W,. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16: 528-36.
13. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-9. (Pubitemid 41565913)
14. Tang Y, Zhao W, Chen Y, et al. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-26. (Pubitemid 351636297)
15. Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2: 1360-8. (Pubitemid 350176266)
16. Audrito V, Vaisitti T, Rossi D, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 2011; 71: 4473-83.
17. Park SY, Lee KB, Lee MJ, et al. Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth. J Cell Physiol 2012; 227: 899-908.
18. Nahimana A, Attinger A, Aubry D, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009; 113: 3276-86.
19. Zoppoli G, Cea M, Soncini D, et al. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010; 38: 979-88.
20. Cea M, Soncini D, Fruscione F, et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PloS One 2011; 6: e22739.
21. Galli M, Van Gool F, Rongvaux A, et al. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 2010; 70: 8-11.
22. Dan L, Klimenkova O, Klimiankou M, et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012; 97: 551-9.
23. Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev 2008; 9: 402-12. (Pubitemid 351574202)
24. Komatsu N, Nakagawa M, Oda T, et al. Depletion of intracellular NAD(+) and ATP levels during ricin-induced apoptosis through the specific ribosomal inactivation results in the cytolysis of U937 cells. J Biochem 2000; 128: 463-70.
25. Hasmann M, Schemainda I,. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-42. (Pubitemid 37413486)
26. Yamaguchi H, Woods NT, Piluso LG, et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 2009; 284: 11171-83.
27. Brooks CL, Gu W,. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011; 2: 456-62.
28. Verdin E,. AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. Mol Cell 2007; 28: 354-6. (Pubitemid 350030567)
29. Gu W, Luo J, Brooks CL, et al. Dynamics of the p53 acetylation pathway. Novartis Found Symp 2004; 259: 197-205; discussion 7, 23-5.
30. Li L, Wang L, Li L, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-81.
31. Thakur BK, Dittrich T, Chandra P, et al,. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun 2012; 424: 371-7.
32. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74. (Pubitemid 24108052)
33. Li Y, Jenkins CW, Nichols MA, et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9: 2261-8. (Pubitemid 24228676)
34. Wagner AJ, Kokontis JM, Hay N,. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 1994; 8: 2817-30.
35. Miyashita T, Reed JC,. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
36. Williams O,. Flow cytometry-based methods for apoptosis detection in lymphoid cells. Methods Mol Biol (Clifton, N.J.) 2004; 282: 31-42.
37. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-8. (Pubitemid 34250107)
38. Tang X, Zhu Y, Han L, et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Investig 2007; 117: 3753-64. (Pubitemid 350224086)
39. Kim MY, Zhang T, Kraus WL,. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 2005; 19: 1951-67.
40. Oei SL, Keil C, Ziegler M,. Poly(ADP-ribosylation) and genomic stability. Biochem Cell Biol 2005; 83: 263-9. (Pubitemid 41297196)
41. Shackelford RE, Bui MM, Coppola D, et al. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 2010; 3: 522-7.
42. Wang B, Hasan MK, Alvarado E, et al. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2011; 30: 907-21.
43. Jang KY, Kim KS, Hwang SH, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41: 366-71.
44. Zhao G, Cui J, Zhang JG, et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 2011; 18: 920-8.
45. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009; 15: 151-8.
46. van der Veer E, Ho C, O'Neil C, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 2007; 282: 10841-5. (Pubitemid 47100731)
47. Bitterman KJ, Anderson RM, Cohen HY, et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002; 277: 45099-107. (Pubitemid 36159111)
48. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 769-78. (Pubitemid 34158740)
49. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (New York, N.Y.) 2009; 325: 834-40.